drugset
drugset / Trial / NCT06484816

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

NCT06484816 ↗

Phase 1 Recruiting 90 enrolled Shenzhen TargetRx Co., Ltd. Sir Run Run Shaw Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies

Timeline

Start
2024-07-08
Primary completion
2027-02
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TGRX-1942 Unknown 4 mg Oral
Subject TGRX-1942 Unknown 10 mg Oral
Subject TGRX-1942 Unknown 20 mg Oral
Subject TGRX-1942 Unknown 30 mg Oral
Subject TGRX-1942 Unknown 40 mg Oral
Subject TGRX-1942 Unknown 50 mg Oral
Subject TGRX-1942 Unknown 60 mg Oral

Indications

hematopoietic and lymphoid cell neoplasm non-small cell lung carcinoma